Mutations in G Protein Encoding Genes and Chromosomal Alterations in Primary Leptomeningeal Melanocytic Neoplasms

Pathology and Oncology Research

Volumn 21, Issue 2, 2015, Pages 439-447

  Küsters Vandevelde, Heidi V N ^a   van Engen van Grunsven, Ilse A C H ^b   Coupland, Sarah E ^c   Lake, Sarah L ^c   Rijntjes, Jos ^b   Pfundt, Rolph ^b   Küsters, Benno ^b,d   Wesseling, Pieter ^a,b,e   Blokx, Willeke A M ^b   Groenen, Patricia J T A ^b  

^a CANISIUS WILHELMINA HOSPITAL   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF LIVERPOOL   (United Kingdom)

^d MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^e VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Central nervous system; GNA11; GNAQ; Leptomeningeal melanocytic neoplasm; Melanocytoma; Melanoma

Indexed keywords

B RAF KINASE; GLUTAMINE; GUANINE NUCLEOTIDE BINDING PROTEIN; LEUCINE; GNA11 PROTEIN, HUMAN; GNAQ PROTEIN, HUMAN; GUANINE NUCLEOTIDE BINDING PROTEIN ALPHA SUBUNIT;

ADULT; AGED; AMINO ACID SUBSTITUTION; ARTICLE; BRAF GENE; BRAIN TUMOR; CHROMOSOME 10; CHROMOSOME 11; CHROMOSOME 17; CHROMOSOME 18; CHROMOSOME 1P; CHROMOSOME 22; CHROMOSOME 2P; CHROMOSOME 3; CHROMOSOME 4P; CHROMOSOME 6; CHROMOSOME 8P; CHROMOSOME 8Q; CHROMOSOME ABERRATION; CHROMOSOME GAIN; CHROMOSOME LOSS; CHROMOSOME VARIANT; CHROMOSOMES AND CHROMOSOMAL PHENOMENA; CLINICAL ARTICLE; CONTROLLED STUDY; COPY NUMBER VARIATION; FEMALE; GENE; GENE MUTATION; GENETIC ASSOCIATION; GNA11 GENE; GNAQ GENE; HETEROZYGOTE; HISTOPATHOLOGY; HRAS GENE; HUMAN; HUMAN TISSUE; MALE; MELANOCYTOSIS; MELANOMA; MIDDLE AGED; MONOSOMY; MONOSOMY 3; MULTIPLEX LIGATION DEPENDENT PROBE AMPLIFICATION; MUTATIONAL ANALYSIS; NRAS GENE; PRIMARY LEPTOMENINGEAL MELANOCYTIC NEOPLASM; PRIMARY TUMOR; RETROSPECTIVE STUDY; COHORT ANALYSIS; GENETICS; MELANOCYTE; MENINGIOMA; MUTATION; PATHOLOGY; TUMOR GENE;

ADULT; AGED; CHROMOSOME ABERRATIONS; COHORT STUDIES; DNA COPY NUMBER VARIATIONS; FEMALE; GENES, NEOPLASM; GTP-BINDING PROTEIN ALPHA SUBUNITS; GTP-BINDING PROTEINS; HUMANS; MALE; MELANOCYTES; MELANOMA; MENINGEAL NEOPLASMS; MIDDLE AGED; MUTATION; RETROSPECTIVE STUDIES;

EID: 84938064242     PISSN: 12194956     EISSN: 15322807     Source Type: Journal    
DOI: 10.1007/s12253-014-9841-3     Document Type: Article

References (49)

1. Brat DJ, Perry A (2007) Melanocytic lesions. In: Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (eds) WHO classification of tumours of the central nervous system. IARC, Lyon, pp 181–183
2. Bydon A, Gutierrez JA, Mahmood A (2003) Meningeal melanocytoma: an aggressive course for a benign tumor. J Neurooncol 64:259–263
3. Liubinas SV, Maartens N, Drummond KJ (2010) Primary melanocytic neoplasms of the central nervous system. J Clin Neurosci 17:1227–1232
4. Perrini P, Caniglia M, Pieroni M, Castagna M, Parenti GF (2010) Malignant transformation of intramedullary melanocytoma: case report. Neurosurg 67:867–869
5. Uozumi Y, Kawano T, Kawaguchi T, Kaneko Y, Ooasa T, Ogasawara S, Yoshida H, Yoshida T (2003) Malignant transformation of meningeal melanocytoma: a case report. Brain Tumor Pathol 20:21–5
6. Brat DJ, Giannini C, Scheithauer BW, Burger PC (1999) Primary melanocytic neoplasms of the central nervous systems. Am J Surg Pathol 23:745–754
7. Arunkumar MJ, Ranjan A, Jacob M, Rajshekhar V (2001) Neurocutaneous melanosis: a case of primary intracranial melanoma with metastasis. Clin Oncol (R Coll Radiol) 13:52–54
8. Koenigsmann M, Jautzke G, Unger M, Theallier-Janko A, Wiegel T, Stoltenburg-Didinger G (2002) 57-year-old male with leptomeningeal and liver tumors. Brain Pathol 12:519–521
9. Kusters-Vandevelde HV, Klaasen A, Kusters B, Groenen PJ, van Engen-van Grunsven IA, van Dijk MR, Reifenberger G, Wesseling P, Blokx WA (2009) Activating mutations of the GNAQ gene: a frequent event in primary melanocytic neoplasms of the central nervous system. Acta Neuropathol 119:317–23
10. Gessi M, Hammes J, Lauriola L, Dorner E, Kirfel J, Kristiansen G, Zur Muehlen A, Denkhaus D, Waha A, Pietsch T (2012) GNA11 and N-RAS mutations: alternatives for MAPK pathway activating GNAQ mutations in primary melanocytic tumours of the central nervous system. Neuropathol Appl Neurobiol 39:417–25
11. Fuld AD, Speck ME, Harris BT, Simmons NE, Corless CL, Tsongalis GJ, Pastel DA, Hartford AC, Ernstoff MS (2011) Primary melanoma of the spinal cord: a case report, molecular footprint, and review of the literature. J Clin Oncol 29:499–502
12. Onken MD, Worley LA, Long MD, Duan S, Council ML, Bowcock AM, Harbour JW (2008) Oncogenic mutations in GNAQ occur early in uveal melanoma. Invest Ophthalmol Vis Sci 49:5230–5234
13. Van Raamsdonk CD, Bezrookove V, Green G, Bauer J, Gaugler L, O'Brien JM, Simpson EM, Barsh GS, Bastian BC (2009) Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature 457:599–602
14. Van Raamsdonk CD, Griewank KG, Crosby MB, Garrido MC, Vemula S, Wiesner T, Obenauf AC A, Wackernagel W, Green G, Bouvier N, Sozen MM, Baimukanova G, Roy R, Heguy A, Dolgalev I et al (2010) Mutations in GNA11 in Uveal Melanoma. N Engl J Med 363:2191–9
15. Lamba S, Felicioni L, Buttitta F, Bleeker FE, Malatesta S, Corbo V, Scarpa A, Rodolfo M, Knowles M, Frattini M, Marchetti A, Bardell A (2009) Mutational profile of GNAQQ209 in human tumors. PLoS One 4:e6833
16. Hurowitz EH, Melnyk JM, Chen YJ, Kouros-Mehr H, Simon MI, Shizuya H (2000) Genomic characterization of the human heterotrimeric G protein alpha, beta, and gamma subunit genes. DNA Res 7:111–120
17. Markby DW, Onrust R, Bourne HR (1993) Separate GTP binding and GTPase activating domains of a G alpha subunit. Science 262:1895–1901
18. Radhika V, Dhanasekaran N (2001) Transforming G proteins. Oncogene 20:1607–1614
19. Murali R, Wiesner T, Rosenblum MK, Bastian BC (2012) GNAQ and GNA11 mutations in melanocytomas of the central nervous system. Acta Neuropathol 123:457–9
20. Strom RG, Shvartsbeyn M, Rosenblum MK, Hameed MR, Nafa K, Mikolaenko I, Babu RP (2012) Melanocytic tumor with GNA11 p.Q209L mutation mimicking a foramen magnum meningioma. Clin Neurol Neurosurg 114:1197–200
21. Damato B, Dopierala JA, Coupland SE (2010) Genotypic profiling of 452 choroidal melanomas with multiplex ligation-dependent probe amplification. Clin Cancer Res 16:6083–6092
22. Prescher G, Bornfeld N, Hirche H, Horsthemke B, Jockel KH, Becher R (1996) Prognostic implications of monosomy 3 in uveal melanoma. Lancet 347:1222–1225
23. van Dongen JJ, Langerak AW, Bruggemann M, Evans PA, Hummel M, Lavender FL, Delabesse E, Davi F, Schuuring E, Garcia-Sanz R, van Krieken JH, Droese J, Gonzalez D, Bastard C, White HEHE et al (2003) Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia 17:2257–2317
24. Wang Y, Carlton VE, Karlin-Neumann G, Sapolsky R, Zhang L, Moorhead M, Wang ZC, Richardson AL, Warren R, Walther A, Bondy M, Sahin A, Krahe R, Tuna M, Thompson PA et al (2009) High quality copy number and genotype data from FFPE samples using molecular inversion probe (MIP) microarrays. BMC Med Genomics 2:8
25. Bauer J, Kilic E, Vaarwater J, Bastian BC, Garbe C, de Klein A (2009) Oncogenic GNAQ mutations are not correlated with disease-free survival in uveal melanoma. Br J Cancer 101:813–815
26. Koopmans AE, Vaarwater J, Paridaens D, Naus NC, Kilic E, de Klein A (2013) Patient survival in uveal melanoma is not affected by oncogenic mutations in GNAQ and GNA11. Br J Cancer 109:493–496
27. Mitsiades N, Chew SA, He B, Riechardt AI, Karadedou T, Kotoula V, Poulaki V (2011) Genotype-dependent sensitivity of uveal melanoma cell lines to inhibition of B-Raf, MEK, and Akt kinases: rationale for personalized therapy. Invest Ophthalmol Vis Sci 52:7248–7255
28. Wu X, Zhu M, Fletcher JA, Giobbie-Hurder A, Hodi FS (2012) The protein kinase C inhibitor enzastaurin exhibits antitumor activity against Uveal Melanoma. PLoS One 7:e29622
29. von Euw E, Atefi M, Attar N, Chu C, Zachariah S, Burgess BL, Mok S, Ng C, Wong DJ, Chmielowski B, Lichter DI, Koya RC, McCannel TA, Izmailova E, Ribas A (2012) Antitumor effects of the investigational selective MEK inhibitor TAK733 against cutaneous and uveal melanoma cell lines. Mol Cancer 11:22
30. Khalili JS, Yu X, Wang J, Hayes BC, Davies MA, Lizee G, Esmaeli B, Woodman SE (2012) Combination small molecule MEK and PI3K inhibition enhances uveal melanoma cell death in a mutant GNAQ- and GNA11-dependent manner. Clin Canc Res 18:4345–4355
31. Ho AL, Musi E, Ambrosini G, Nair JS, Deraje Vasudeva S, de Stanchina E, Schwartz GK (2012) Impact of combined mTOR and MEK inhibition in uveal melanoma is driven by tumor genotype. PLoS One 7:e40439
32. Carjaval RD. Quevedo F. et al. (2013) Phase II study of selumetinib versus temozolomide in gnaq/gna11 mutation uveal melanoma. In: 2013 ASCO Annual Meeting
33. Chen X. Wu Q. Tan L. Porter D. Jager MJ. C. Emery C. B.C. Bastian BC (2013) Combined PKC and MEK inhibition in uveal melanoma with GNAQ and GNA11 mutations. Oncogene doi: 10.1038/onc.2013.418
34. Wang H, Zhang S, Wu C, Zhang Z, Qin T (2013) Melanocytomas of the central nervous system: a clinicopathological and molecular study. Eur J Clin Invest 43:809–15
35. Pedersen M, Kusters-Vandevelde HV, Viros A, Groenen PJ, Sanchez-Laorden B, Gilhuis JH, van Engen-van Grunsven IA, Renier W, Schieving J, Niculescu-Duvaz I, Springer CJ, Kusters B, Wesseling P, Blokx WA, Marais R (2013) Primary melanoma of the CNS in children is driven by congenital expression of oncogenic NRAS in melanocytes. Cancer Discov 3:458–469
36. Kinsler VA, Thomas AC, Ishida M, Bulstrode NW, Loughlin S, Hing S, Chalker J, McKenzie K, Abu-Amero S, Slater O, Chanudet E, Palmer R, Morrogh D, Stanier P, Healy E, Sebire NJ, Moore GE (2013) Multiple congenital melanocytic nevi and neurocutaneous melanosis are caused by postzygotic mutations in codon 61 of NRAS. J Invest Dermatol 133:2229–36
37. Bafaloukos D, Gogas H (2004) The treatment of brain metastases in melanoma patients. Cancer Treat Rev 30:515–520
38. Greco Crasto S, Soffietti R, Bradac GB, Boldorini R (2001) Primitive cerebral melanoma: case report and review of the literature. Surg Neurol 55:163–168
39. Theunissen P, Spincemaille G, Pannebakker M, Lambers J (1993) Meningeal melanoma associated with nevus of Ota: case report and review. Clin Neuropathol 12:125–129
40. Rodriguez y Baena R, Gaetani P, Danova M, Bosi F, Zappoli F (1992) Primary solitary intracranial melanoma: case report and review of the literature. Surgical Neurol 38:26–37
41. Skarli SO, Wolf AL, Kristt DA, Numaguch Y (1994) Melanoma arising in a cervical spinal nerve root: report of a case with a benign course and malignant features. Neurosurg 34:533–537
42. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K et al (2002) Mutations of the BRAF gene in human cancer. Nature 417:949–954
43. Broekaert SM, Roy R, Okamoto I, van den Oord J, Bauer J, Garbe C, Barnhill RL, Busam KJ, Cochran AJ, Cook MG, Elder DE, McCarthy SW, Mihm MC, Schadendorf D, Scolyer RA, Spatz A, Bastian BC (2010) Genetic and morphologic features for melanoma classification. Pigment Cell Melanoma Res 23:763–770
44. van den Bosch BT, Kilic E, Paridaens D, de Klein A (2010) Genetics of uveal melanoma and cutaneous melanoma: two of a kind? Dermatol Res Pract 360136
45. Parrella P, Sidransky D, Merbs SL (1999) Allelotype of posterior uveal melanoma: implications for a bifurcated tumor progression pathway. Cancer Res 59:3032–3037
46. Cruz F, Rubin BP, Wilson D, Town A, Schroeder A, Haley A, Bainbridge T, Heinrich MC, Corless CL (2003) Absence of BRAF and NRAS mutations in uveal melanoma. Cancer Res 63:5761–5766
47. Kilic E, Bruggenwirth HT, Verbiest MM, Zwarthoff EC, Mooy NM, Luyten GP, de Klein A (2004) The RAS-BRAF kinase pathway is not involved in uveal melanoma. Melanoma Res 14:203–205
48. Weber A, Hengge UR, Urbanik D, Markwart A, Mirmohammadsaegh A, Reichel MB, Wittekind C, Wiedemann P, Tannapfel A (2003) Absence of mutations of the BRAF gene and constitutive activation of extracellular-regulated kinase in malignant melanomas of the uvea. Lab Invest 83:1771–1776
49. Janssen CS, Sibbett R, Henriquez FL, McKay IC, Kemp EG, Roberts F (2008) The T1799A point mutation is present in posterior uveal melanoma. Br J Cancer 99:1673–1677